Meta-analysis of controlled clinical trials of nimotuzumab combined with chemoradiotherapy in advanced esophageal cancer
Abstract
Introduction: There is growing evidence that nimotuzumab combined with chemoradiotherapy may be effective and safe in patients with advanced esophageal cancer.
Objective: Evaluate the clinical efficacy and safety of nimotuzumab combined with conventional therapy by means of a systematic review and meta-analysis of randomized controlled clinical trials.
Methods: A meta-analysis was conducted of randomized controlled trials retrieved from PubMed and ClinicalTrials.gov. Free and topic search terms were used. The primary outcome was overall survival, expressed as a risk rate with a 95% confidence interval. Disease control indices, objective response and toxicity were also evaluated. The study complied with the PRISMA guidelines.
Results: Seven studies were included, with 443 patients evaluated from 2012 to 2018. In general terms, treatment with nimotuzumab significantly improved survival (RH: 0.71; CI 95%: 0.57-0.89; p < 0.002), the disease control index (RR: 1.15; CI 95%: 1.01-1.31, p < 0.04) and the objective response index (RR: 1.39; CI 95%: 1.20-1.61, p < 0.0001). Treatment with nimotuzumab slightly increased hematological toxicity and diarrhea, but it was tolerable, and significant differences were not found in adverse events between the two groups. There was publication bias.
Conclusions: Nimotuzumab combined with chemoradiotherapy significantly improved the disease control index, objective response and survival in patients with advanced esophageal cancer with an acceptable safety profile.
Key words: nimotuzumab, esophageal cancer, epidermal growth factor receptor, meta-analysis.Downloads
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.
2. Ministerio de Salud Pública. Anuario Estadístico de Cuba 2019. MINSAP, Dirección Nacional de Registros Médicos y Estadísticas de Salud: La Habana. 2020 [acceso 20/07/2021]. Disponible en: https://files.sld.cu/bvscuba/files/2020/05/AnuarioElectrónico-Español-2019-ed-2020.pdf
3. Galán Y, Iglesias Y, Kindelan G, Planas S, Fernandez LM. Incidencia de cáncer en Cuba en el 2016. Rev Cub Oncol. 2020;18(3): e_46. [acceso 20/07/2021]. Disponible en: http://revoncologia.sld.cu/index.php/onc/article/view/46/36
4. World Health Organization (WHO). Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019. WHO; 2020. [acceso 30/05/2021]. Disponible en: who.int/data/gho/data/themes/mortality-andglobal-health-estimates/ghe-leadingcauses-of- death
5. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017; 390:2383-96. doi:10.1016/S0140-6736(17)31462-9.
6. Yang J, Liu X, Cao S, Dong X, Rao S, Cai K. Understanding esophageal cancer: the challenges and opportunities for the next decade. Front Oncol. 2020;10:1727. doi:10.3389/fonc.2020.01727
7. Rajaram P, Chandra P, Ticku S, Pallavi BK, Rudresh KB, Mansabdar P. Epidermal growth factor receptor: Role in human cancer. Indian J Dent Res. 2017;28(6):687-94. doi:10.4103/ijdr.IJDR_534_16.
8. Yoshioka M, Ohashi S, Ida T, Nakai Y, Kikuchi O, Amanuma Y, et al. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res. 2017;36(1):101. doi: 10.1186/s13046-017-0572-7.
9. Hirano H, Kato K. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol. 2019;49(5):412-420. doi: 10.1093/jjco/hyz034.
10. Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T. Nimotuzumab: beyond the EGFR signaling cascade inhibition. Semin Oncol. 2018;45(1-2):18-26. doi:10.1053/j.seminoncol.2018.04.008.
11. Xu S, Ramos-Suzarte M, Bai X, Xu B. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: A single institute experience. Oncotarget. 2016;7:33391-407. doi:10.18632/oncotarget.8516.
12. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, 2019.
13. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Washington: November 27, 2017. [acceso 15/07/2021]. Disponible en: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi:10.1136/bmj.n71.
15. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther. 2012;13(8):600-5. doi: 10.4161/cbt.19849.
16. Sun CJ, Chen Y. The clinical research of Nimotuzumab combined with radiotherapy and chemotherapy for advanced esophageal cancer. J Clin Med Liter. 2014;1:2346–8.
17. Wu CR, Zhang QZ, Yang W. Clinical study on Nimotuzumab combined with intensity- modulated radiotherapy and chemotherapy for esophageal cancer. J Chin Oncol. 2014;20:500–3.
18. Luo HT, Liang CX. Effect of intensity-modulated radiotherapy combined with docetaxel and Nimotuzumab in treatment of patients with esophageal carcinoma. Modern Oncol. 2015;23:219-22.
19. Chen YL, SP L, Lian YN. Clinical study on Nimotuzumab combined with nadaplatin concurrent chemoradiotherapy for local advanced esophageal carcinoma. J North Pharm. 2016;13:140-1.
20. Fu GL. Curative effect of Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced esophageal carcinoma. Chin J Prim Med Pharm. 2017;24:3457-61.
21. de Castro Junior G, Segalla JG, de Azevedo SJ, Andrade CJ, Grabarz D, de Araújo Lima França B, et al. A randomized phase II study of chemoradiotherapy with or without Nimotuzumab in locally advanced oesophageal cancer: NICE trial. Eur J Cancer. 2018;88:21-30. doi:10.1016/j.ejca.2017.10.005.
22. Yang YM, Hong P, Xu WW, He QY, Li B. Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020;5(1):229. doi:10.1038/s41392-020-00323-3.
23. Huang ZH, Ma XW, Zhang J, Li X, Lai NL, Zhang SX. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials. BMC Cancer. 2018;18(1):1170. doi:10.1186/s12885-018-5040-z
24. Jing W, Yan W, Liu Y, Li J, Yu J, Zhu H. Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Biol Ther. 2019;20(8):1121-6. doi:10.1080/15384047.2019.1598760.
25. Wang T, Yu J, Liu M, Chen Y, Zhu C, Lu L, et al. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies. Drug Des Devel Ther. 2019;13:539-53. doi: 10.2147/DDDT.S189514
26. Lima-Pérez M, Soriano-García JL, López-Díaz L, Fleites-Calvo V, Domínguez-Alvarez C, González-Meisozo M, et al. Nimotuzumab combinado con quimiorradioterapia en pacientes con carcinoma epidermoide esofágico avanzado en el mundo real. Rev Cubana Invest Bioméd. 2021[acceso 15/07/2021];40(5):e1564. Disponible en: http://www.revibiomedica.sld.cu/index.php/ibi/article/view/1564.
27. Berger C, Krengel U, Stang E, Moreno E, Madshus IH. Nimotuzumab and cetuximab block ligand independent EGF receptor signaling efficiently at different concentrations. J Immunother. 2011;34:550-5. doi:10.1097/CJI.0b013e31822a5ca6.
28. Han X, Lu N, Pan Y, Xu J. Nimotuzumab combined with chemotherapy is a promising treatment for locally advanced and metastatic esophageal cancer. Med Sci Monit. 2017;23:412-8. doi:10.12659/msm.902645.
29. Concha-Benavente F, Ferris RL. Reversing EGFR mediated immunoescape by targeted monoclonal antibody therapy. Front Pharmacol. 2017; 30(8):332. doi: 10.3389/fphar.2017.00332.
30. Mazorra Z, Lavastida A, Concha-Benavente F, Valdés A, Srivastava RM, García-Bates TM, et al. Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T cells in head and neck cancer patients. Front Pharmacol. 2017;8:382. doi: 10.3389/fphar.2017.00382.
31. Saumell Y, Sanchez L, González S, Ortiz R, Medina E, Galán Y, et al. Overall survival of patients with locally advanced or metastatic esophageal squamous cell carcinoma treated with nimotuzumab in the real world. Adv Ther. 2017;34(12):2638-47. doi: 10.1007/s12325-017-0631-7
32. Luo HQ, Han L, Jiang Y. Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer. Asian Pac J Cancer Prev. 2014;15(13):5343-8. doi:10.7314/apjcp.2014.15.13.5343.
33. Tundidor Y, Ponce LF, Chao L, Solozábal J, Hust M, Dübel S, Rojas G. Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity. Sci Rep. 2020;10(1):1194. doi:10.1038/s41598-019-57279-w.
34. Miroddi M, Sterrantino C, Simonelli I, Ciminata G, Phillips RS, Calapai G. Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials. Crit Rev Oncol Hematol. 2015;96(2):355-71. doi:10.1016/j.critrevonc.2015.06.004.
35. Owczarek W, Słowińska M, Lesiak A, Ciążyńska M, Maciąg A, Paluchowska E, et al. The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. Postepy Dermatol Alergol. 2017;34(5):418-28. doi: 10.5114/ada.2017.71106.
Downloads
Published
How to Cite
Issue
Section
License
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.
Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.
El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.
